ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer.
$1.16+0.43%
报价 2026-11-06
市值
$159.7M
EV
$176.5M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -55.6%
$0.89$2.60
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALXOALX Oncology Holdings Inc. | $159.7M | +0.4% | +666.7% | 0% | – | – | – | |
| DTILPrecision BioSciences, Inc. | $292.6M | +7.4% | +125.3% | 98.7% | – | – | – | |
| ARTVArtiva Biotherapeutics, Inc. | $202.9M | +0.5% | -100.0% | 0% | – | – | – | |
| STROSutro Biopharma, Inc. | $159.5M | +4.6% | -66.8% | 98.7% | – | – | – | |
| IMUXImmunic, Inc. | $105.7M | +5.9% | -96.9% | 0% | – | – | – | |
| BMEABiomea Fusion, Inc. | $41M | -3.5% | +20.0% | 0% | – | – | – | |
| MGXMetagenomi, Inc. Common Stock | $26.8M | -2.9% | -57.7% | 0.3% | – | – | – | |
| ATYRaTyr Pharma, Inc. | $15.6M | +5.3% | +3800.0% | -11,967.9% | – | – | – | |
| GUTSFractyl Health, Inc. Common Stock | $12.3M | +3.8% | +153.1% | 0% | – | – | – | |
| 同行中位数 | – | – | -18.8% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。